Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Britain Courts Anthropic Amid US Defense Department Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Dutch healthcare technology giant Philips (EPA:TTEF) forecasted a 1% to 3% increase in comparable sales for 2025 despite ongoing challenges in China. The company missed market expectations for Q4 2024, reporting €5.04 billion ($5.27 billion) in revenue, slightly below analysts’ projections of €5.07 billion.
Philips attributed the weaker performance to a double-digit decline in China sales, which is expected to continue in 2025. The forecast includes a mid- to high-single-digit drop in Chinese revenue and the impact of new U.S.-China tariffs. CEO Roy Jakobs previously stated that China’s contribution to total revenue has fallen to around 10%, down from over 13% earlier in the decade. The company employs over 7,000 people in the country.
Despite the decline, Philips maintained its commitment to growth, with adjusted EBITA reaching €679 million for Q4, slightly below the €683 million analysts expected. The company proposed an annual dividend of €0.85 per share, consistent with the previous year.
Philips, known for its diverse portfolio from medical imaging systems to consumer electronics, had already lowered its 2024 sales forecast in October due to weak demand in China. The company’s ability to navigate global economic shifts, supply chain disruptions, and geopolitical challenges will be critical for its 2025 performance.
With a focus on stabilizing sales and overcoming market headwinds, Philips continues to adapt its strategy amid evolving economic conditions.
